Generic or biosimilar · Side effects · Cost · Tysabri for MS · Other uses · FAQ · Dosage · Alternatives · Tysabri vs. Kesimpta · Tysabri vs. Ocrevus · How it’s given · Pregnancy · Breastfeeding · Tysabri and alcohol · Interactions · Tysabri vs. Humira · How it works · Precautions · For professionals
Natalizumab (Tysabri) is a treatment for people with relapsing forms of MS. It makes flares happen less often and keeps physical disabilities from getting worse quickly. Tysabri works in a...
Tysabri ; Generic Name: natalizumab · Brand Name: Tysabri · Drug Class: Inflammatory Bowel Disease Agents, Monoclonal Antibodies, Integrin Blockers
HIV infection or AIDS · leukemia or lymphoma · an organ transplant · other medical conditions that can weaken your immune system
Official answer: Yes, treatment with Tysabri can weaken your immune system. This may increase your risk of getting an unusual or...
For this reason, it’s important to talk with your doctor if you’re interested in stopping your Tysabri treatment. Your doctor can discuss other treatment options for your condition. No...
Tysabri is administered via intravenous (IV) infusion, which involves delivering the medication through a needle placed in your vein. ; The recommended dose of Tysabri is 300mg and this is infused in 100ml of 0.9% sodium chloride injection, USP, over one hour every four weeks. The infusion rate is about 5mg per minute. ; During the Tysabri infusion and for one hour after patients are monitored for any signs of a hypersensitivity-type reaction to the infusion.
These factors should be considered in the context of expected benefit when initiating and continuing treatment with TYSABRI(5.1) • Monitor patients, and withhold TYSABRI immediately at...
There may be other risk factors for getting PML during TYSABRI treatment that we do not know about yet. Your doctor should discuss the risks and benefits of TYSABRI treatment with you...
Safety Announcement · Additional Information for Patients · Additional Information for Healthcare Professionals · Data Summary · Safety Announcement · Additional Information for Patients